By facilitating whole-genome sequencing we can help in taking swift treatment decisions
Redcliffe Life Sciences is keen to work with the ICMR and NIV to understand various strains of the COVID-19 virus and its patterns. informs Ashish Kumar, Dubey, COO & Co-Founder, Redcliffe Life Sciences as he talks about how whole genome sequencing can help in predicting the response of drugs on each such viral strain, with Usha Sharma
Tell us about Redcliffe Lifesciences’ ongoing activities and its work towards tackling COVID-19 pandemic.
Redcliffe was an initial investor in Mylab in 2017 when it was a company unknown outside Pune. The company made an investment of Rs 65 lakh in Mylab to help them with the automation of tests in a pooled capacity. It is this automation which has now proven to be a most useful technology for diagnosis of COVID-19. Redcliffe Life Sciences also filed two BIRAC proposals for in silico testing of existing drugs. It was successful on SARS-COV1 and new peptides, which is highly promising.